1. S. Kahwaji and M.A. White, 2018. “Data supporting the prediction of the properties of eutectic organic phase change materials”, Data in Brief, 17, 724.

  2. S. Kahwaji and M.A. White, 2018. “Prediction of the properties of eutectic fatty acid phase change materials”, Thermochimica Acta, 660, 94.

  3. Caplette J., Frigo T., Jozwiakowski M., Shea H., Mirmehrabi M., Müller P., 2017. "Characterization of new crystalline forms of hydroxyprogesterone caproate", International Journal of Pharmaceutics, 527 (1), 42-51.

  4. Kermanshahi pour A., MacEachern L., Mirmehrabi M., 2017. “A novel process for preparation of fatty acid oil mixture in solid form, Food Chemistry, 229, 50-56.

  5. J.A. Noël, S. Kahwaji, M.A. White, 2017. “Molecular structure and melting: Implications for phase change materials”, Canadian Journal of Chemistry, cjc-2017-0578.

  6. Mayo, R.A.; Sullivan, D.J.; Fillion, T.A.P.; Kycia, S.W.; Soldatov, D.V. and Preuss, K.E., 2017. “Reversible Crystal-to-Crystal Chiral Resolution: Making/Breaking Non-bonding S⋯O InteractionsChem. Commun., 53, 3964-3966.

  7. S. Kahwaji and M.A. White, 2017. “A computational tool to predict the compositions, latent heats of fusion and melting temperatures of eutectic mixtures of organic phase change materials (PCMs)”, Mendeley Data, 10.17632/243d6r4z26.1.

  8. C. P. Romao, F. A. Perras, U. Werner-Zwanziger, J. A. Lussier, K. J. Miller, C. M. Calahoo, J. W. Zwanziger, M. Bieringer, B. A. Marinkovic, D. L. Bryce and M. A. White, 2015. “Zero Thermal Expansion in ZrMgMo3O12: NMR Crystallography Reveals Origins of Thermoelastic Properties” Chemistry of Materials 27 2633–2646. Supporting Information.

  9. MacEachern L., A. Sylvester, A. Flynn, A. Rahmani, and M. R. Morrow, Langmuir, 2013. "Dependence of Bicellar System Phase Behavior and Dynamics on Anionic Lipid Concentration", 29 (11) 3688 - 3699.
  10. A. C. Torres Dias, C. Luz Lima, W. Paraguassa, K. Pereira da Silva, P.T.C. Freire, B. Marinkovic, F. Rizzo, K. J. Miller, M. A. White, A. G. Souza Filho, 2013. “Pressure-induced crystal-amorphous transformation in Y2Mo3O12Vibrational Spectroscopy, 68, 251-256.

  11. K. J. Miller, M. B. Johnson, M. A. White, M. Mario Bieringer, B. A. Marinkovic, 2013. “Near-zero thermal expansion in In(HfMg)0.5Mo3O12,” Journal of the American Ceramic Society, 96, 561-566.

  12. Chitnis, S., MacDonald, E., Burford, N., Werner-Zwanziger, U., MacDonald, R., 2012. “P_P Menschutkin preparation of prototypical phosphinophosphonium SaltsChem. Commun., 48, 7359-7361. 

  13. K. J. Miller, M. B. Johnson, M. A. White, B. A. Marinkovic, 2012. “Low-temperature investigations of the open framework material HfMgMo3O12,” Solid State Communications, 152, 1748-1752.

  14. C.P. Romao, K.J. Miller, C.A. Whitman, M.A. White, B.A. Marinkovic, 2012. “Negative thermal expansion (thermomiotic) materials,” in press in Comprehensive Inorganic Chemistry 2, K. Poeppelmeier, Ed.

  15. M. Ari, K. J. Miller, B. A. Marinkovic, P. M. Jardim, F. Rizzo, M. A. White, Paper, 2011. “Rapid synthesis of the low thermal expansion phase of Al2Mo3O12 via a sol-gel method using polyvinyl alcohol,” Journal of Sol-Gel Science and Technology, 58, 121-125.

  16. L'Heureux, A., F. Beaulieu, C. Bennett, D.R. Bill, S. Clayton, F. La Flamme, M. Mirmehrabi, S. Tadayon, D. Tovell and M. Couturier, 2010. “Aminodifluorosulfinium Salts: Selective Fluorination Reagents with Enhanced Thermal Stability and Ease of Handling”, Journal of Organic Chemistry, 75(10), 3401-3411.

  17. B. A. Marinkovic, M. Ari, R. R. de Avillez, F. Rizzo, F. F. Ferreira, K. J. Miller, M. B. Johnson, M. A. White, 2009. “Correlation between AO6 polyhedral distortion and negative thermal expansion in orthorhombic Y2Mo3O12 and related materials,” Chemistry of Materials, 21, 2886-2894. (Highlighted by the Brazilian Synchrotron Light Laboratory).

  18. Trifkovic M., S. Rohani, and M. Mirmehrabi, 2007. “Polymorphic Generation through Solvent Selection: Ranitidine Hydrochloride”, Organic Process Research & Development, 11(1), 138-143.

  19. Mirmehrabi M., S. Rohani, K.S.K Murthy and B. Radatus, 2006. “Polymorphic Behavior and Crystal Habit of an Anti-Viral/HIV Drug: Stavudine”, Crystal Growth and Design (American Chemical Society), 6(1), 141-149.

  20. Mirmehrabi M., Rohani S., and L. Perry, 2006. “Predicting Solubilities of Pharmaceutical Compounds”, Chemical Engineering Progress, 102(12), 6, 20-21.

  21. Mirmehrabi M., S. Rohani and L. Perry, 2006. “Thermodynamic Modeling of Activity Coefficient and Prediction of Solubility: Part 1. Predictive Models”, Journal of Pharmaceutical Sciences, 95(4), 790-797.

  22. Mirmehrabi M., S. Rohani and L. Perry, 2006. “Thermodynamic Modeling of Activity Coefficient and Prediction of Solubility: Part 2. Semi-Predictive or Semi-Empirical Models”, Journal of Pharmaceutical Sciences, 95(4), 798-809.

  23. M. Tabbal, S. Kahwaji, T. Christidis, B. Nsouli, and K. Zahraman, 2006. “Pulsed laser deposition of nanostructured dichromium trioxide thin films”, Thin Solid Films, 515, 1976.

  24. Mirmehrabi, M., S. Rohani, M. C. Jennings, 2005. “Stavudine”, Acta Crystallographica, Section C: Crystal Structure Communications, C61(12), 695-698.

  25. Mirmehrabi M. and S. Rohani, 2004. “An Approach to Solvent Screening for Crystallization of Polymorphic Pharmaceuticals and Fine Chemicals”, Journal of Pharmaceutical Sciences, 94 (7), 1560-1576.

  26. Mirmehrabi M., S. Rohani, K.S.K Murthy and B. Radatus, 2004. “Improving the Filterability and Solid Density of Ranitidine Hydrochloride Form 1”, Journal of Pharmaceutical Sciences, 93 (7), 1692-1700.

  27. Mirmehrabi M., S. Rohani, K.S.K Murthy and B. Radatus, 2004. “Solubility, Dissolution Rate and Phase Transition Studies of Ranitidine Hydrochloride Tautomeric Forms”, International Journal of Pharmaceutics, 282(1-2), 73-85.

  28. Mirmehrabi M., S. Rohani, K.S.K. Murthy and B. Radatus, 2004. “Characterization of Tautomeric Forms of Ranitidine Hydrochloride: Thermal Analysis, Solid-State NMR, X-ray”, Journal of Crystal Growth, 260, 517-526.

  29. Mirmehrabi M. and S. Rohani, 2004. “Measurement and Prediction of the Solubility of Stearic Acid Polymorphs by the UNIQUAC Equation”, Canadian Journal of Chemical Engineering, 82 (2), 335-342.

  1. Reddy J.P., Mirmehrabi M., Kota M., Dash U., 2019. “Process of making somatostatin modulators”, US Patent 10,464,918

  2. Mirmehrabi M., 2018, “Crystalline and amorphous forms of 17-alpha-hydroxyprogestrone caproate”, US Patent App. 2018282366A1

  3. Matharu S., Heinrich B., Singh A., Mirmehrabi M., 2018. “Process of preparing low ABUK oxymorphone hydrochloride”, US Patent 9918979B2

  4. Mollard P., Cornell C.R., Wesson K.E., Giannousis P., Suchit S., Mirmehrabi M., 2018. Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide”, US Patent Application 20180000749A1

  5. Andres P., Datar Y., Gadiraju R., Kowalczyk B. A., Kuklis G. C., Mirmehrabi M., Paschalides N., 2017. Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof”, European Patent EP2914599B1

  6. Heinrich B.W., Gou D.M., Mirmehrabi M., Paul B., Coughlin D.J. 2017. “Pharmaceutically acceptable salts and polymorphic forms of hydrocodone benzoic acid enol ester and processes for making same”, US Patent 9815844B2

  7. Singidi R.K.R., Gududuru V., Mirmehrabi M., Thompson K.E., Tigyi G.J., Yates C.R., Strobos J., 2017. “Crystalline salts of (Z)-O-octadec-9-en-1-yl O,O-dihydrogen phosphorothioate”, US 15429972

  8. Singh A., Mirmehrabi M., 2015. “Crystalline forms of silodosin”, US Patent App. 20160194281A1

  9. Singh A., Mirmehrabi M., 2015. “Forms of oxymorphone hydrochloride”, US Patent 9,062,063 B1

  10. Paschalidis N., Mirmehrabi M., 2015. Crystalline forms of morphine sulfate”. US Patent 9,145,420B1

  11. Mollard P., Giannousis P., Mirmehrabi M., Alite H., Singh A., 2014. “Methods for chiral resolution of trolox”, US Patent App. 20180002247A1

  12. Brittain J., Stanley C., Kolchinski A., Mirmehrabi M., Bell D., 2013. “Synthesis and formulations of porphyrin compounds”, US Patent App. 20160333019A1

  13. Lu Q., Ku MS, Chew W, Cheal GK, Hadfield AF, Mirmehrabi M, 2012. “Preparation of maleate salt of neratininb and its use”, EP Patent 2,537,843

  14. Lu Q., Ku MS, Chew W, Cheal GK, Hadfield AF, Mirmehrabi M, 2012. “Maleate Salts of (E)-N--4-(Dimethylamino)-2-Butenamide and Crystalline Forms Thereof”, US Patent 20,120,289,545

  15. Lu Q., Ku MS, Chew W, Cheal GK, Hadfield AF, Mirmehrabi M, 2011. “Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-2-buteramide and crystalline forms thereof”, US Patent App. 13/181,37

  16. Chew W, Wang Z, Nencini A, Zanaletti R, Cheal G, Bertrand M, Potoski J, Mirmehrabi M, 2009. “Synthesis of pyrazoles”, WO Patent 2,009,091,832

  17. Lu Q., Ku MS, Chew W, Cheal GK, Hadfield AF, Mirmehrabi M, 2012. “Maleate Salts of (E)-N--4-(Dimethylamino)-2-Butenamide and Crystalline Forms Thereof”, US Patent 20,120,289,545

  18. Lu Q., Ku MS, Chew W, Cheal GK, Hadfield AF, Mirmehrabi M, 2011. “Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-2-buteramide and crystalline forms thereof”, US Patent App. 13/181,37

  19. Mirmehrabi M, Nencini A, Zanaletti R, Tadayon A, Deshmukh S, 2009, “Compound forms and uses thereof”, WO Patent 2,009,091,831

  20. Alimardanov AR, Krishnan L, Zhou M, Wang TZ, Ren J, Considine JL, WU CC, Brazzillo J, Raveendranath P, Sutherland KW, Mirmehrabi M, Deshmukh S, 2009. “Synthesis of pyrrolidine compounds", EP Patent 2,074,087

  21. Krishnan MK, Ghorab M, Carson RW, Hasan S, Nagi A, Tadayon A, Iera S, Mirmehrabi M, 2009. “Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benoxazol-5-ol and pharmaceutical formulations thereof”, EP Patent 2,064,195

  22. Alimardanov AR, Sutherland KW, Mirmehrabi M, Deshmukh S, Krishnan L, Zhou M, Wang TZ, Ren J, Considine JL, Wu CC, Brazzillo J, Raveendranath P, 2009, “Synthesis of pyrrolidine compounds”, EP Patent 2,468,724

  23. Lu Q, Ku M, Chew W, Cheal G, Hadfield A, Mirmehrabi M, 2009. “Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy) anilino]-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-2-buteramide and crystalline forms thereof”, WO Patent 2,009,052,264

  24. Mirmehrabi M, Tadayon A, Deshmukh S, Nencini A, Zanaletti R,2009. ” Compound forms and uses thereof”, US Patent App. 12/353,891

  25. Chew W, Wang Z, Cheal G, Bertrand M, Potoski J, Mirmehrabi M, Nencini A, Zanaletti R, 2009. “Synthesis of pyrazoles”, US Patent App. 12/353,896

  26. Mirmehrabi M, Niu Y, Tadayon A, Deshmukh S, Ku MS, 2008, “Synthesis and characterization of polymorph form II of 4-(2-(4, 4-dimethyl-2-oxooxazolidin-3-YL) thiazol-4-YL) benzonitrile”, US Patent App. 12/075,228

  27. Mirmehrabi M, Tadayon A, Deshmukh S, 2008. “Synthesis and characterization of polymorph form III 4-(2-(4, 4-dimethyl-2-oxooxazolidin-3-yl) thiazol-4-yl) benzonitrile”, US Patent App. 12/075,248

  28. Deshmukh S., Mirmehrabi M, 2008. “Methods for preparing crystalline rapamycin and for measuring crystallinity of rapamycin compounds using differential scanning calorimetry”. EP Patent 1,957,964

  29. Deshmukh S, Mirmehrabi M, 2008. “Methods for preparing crystalline rapamycin and for measuring crystallinity of rapamycin compounds using differential scanning calorimetry”. WO Patent 2,007,067,566

  30. Mirmehrabi M, Niu Y, Tadayon A, Deshmukh S, Ku MS, 2008. “Synthesis and characterization of polymorph form III 4-(2-(4, 4-dimethyl-2-oxooxazolidin-3-yl) thiazol-4-yl) benzonitrile”, WO Patent 2,008,112,498

  31. Mirmehrabi M, Tadayon A, Deshmukh S, 2008. “Synthesis and characterization of polymorph form III 4-(2-(4, 4-dimethyl-2-oxooxazolidin-3-yl) thiazol-4-yl) benzonitrile”, WO Patent 2,008,112,495

  32. Deshmukh S, Ali K, Diorio CR, Ehrnsperger EC, Fawzi MB, Shah SM, Mirmehrabi M, 2008. “Glucuronate salt of a piperazine compound”, EP Patent 1,940,830

  33. Mirmehrabi M, Megati S, Tadayon A, Deshmukh S, 2008. “Crystalline forms and polymorphs of n-(3-(dimethylamino) propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as succinate salts”, US Patent App. 12/105,443

  34. Mirmehrabi M, Tadayon A, Deshmukh S, 2008. “Crystalline polymorphs of n-(3-(dimethylamino) propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as d-glucoronate salts”, US Patent App. 12/105,520

  35. Mirmehrabi M, Tadayon A, Deshmukh S, 2008, “Crystalline polymorphs of n-(3-(dimethylamino) propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as acetate saltsUS Patent App. 12/105,507

  36. Mirmehrabi M, Megati S, Tadayon A, Deshmukh S, 2008. “Crystalline forms and polymorphs of n-(3-(dimethylamino) propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as pharmaceutically acceptable salts”, US Patent App. 12/105,567

  37. Papamichelakis M, Lunetta JF, Lankau M, Richard L, Kendall C, Saraiva MC, Wen X, Mirmehrabi M, Paquet V, Daigneault S, Zhang P, 2008, “Methods for the preparation of hydroxy-substituted aryl sulfamide compounds”, US Patent App. 12/332,400

  38. Bernatchez M, Chew W, Daigneault S, Palus E, Mirmehrabi M, Bouchard L, 2008. ”Tigecycline and methods of preparing intermediates”. US Patent App. 12/251,488

  39. Krishnan M, Ghorab M, Carson R, Hasan S, Nagi A, Tadayon A, Iera S, Mirmehrabi M, 2008. “Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1, 3-benzoxazol-5-ol and pharmaceutical formulations thereof”, WO Patent 2,008,064,217

  40. Mirmehrabi M, Considine JL, Niu Y, Tadayon A, Deshmukh S, Liang JQ, Wu Y, 2008.“Polymorphs, solvates, and hydrate of 5-(4'-fluoro-2'-oxo-1', 2'-dihydrospiro [cyclopropane-1, 3'-indol]-5'-yl)-1-methyl-1h-pyrrole-2-carbonitrile”, US Patent App. 12/138,852

  41. Deshmukh S, Ali K, Diorio CR, Ehrnsperger EC, Fawzi MB, Shah SM, Mirmehrabi M, 2007. “Glucuronate salt of a piperazine compound”, WO Patent 2,007,033,191

  42. Mirmehrabi M, Yu Q, Tadayon A, Tesconi M, Xu Y, 2007. ”Crystal forms of (S)-(8 (2, 6-dichlorophenyl)-6-fluoro-2, 3-dihydro benzo [b][1, 4] dioxin-2-yl) methanamine hydrochloride salt”, US Patent App. 11/787,633

  43. Tadayon A, Ierq S, Mirmehrabi M, 2007. “Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1, 3-benzoxazol-5-ol”, US Patent App. 11/943,102

  44. Tadayon A, Ierq S, Mirmehrabi M, 2007. “Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1, 3-benzoxazol-5-ol“, US Patent App. 11/942,941

  45. Tadayon A, Ierq S, Mirmehrabi M, 2007. “Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1, 3-benzoxazol-5-ol”, US Patent App. 11/943,076

  46. Tadayon A, Ierq S, Mirmehrabi M, 2007. “Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1, 3-benzoxazol-5-ol”,US Patent App. 11/942,897

  1. Kermanshahi pour A., MacEachern L., Mirmehrabi M., 2018.A Novel Process for Preparation of Fatty Acid Oil Mixture in Solid Form”, Gordon Research Conference- Crystal Engineering.

  2. R. Alex Mayo, Kathryn E. Preuss, 2016. “Phase Transition Behaviour of a Dimorphic System: The Role of Intermolecular Contacts Involving Sulfur”, Crystal Engineering and Emerging Materials Workshop of Ontario and Quebec, CEMWOQ-3, Windsor, ON, Canada. 

  3. MacEachern L., Mirmehrabi M., 2016. "Quantification of Polymorphs in Solid Mixtures by Powder X-Ray Diffraction Using Multivariate Analysis ", AAPS 2016. Poster Presentation.

  4. Mirmehrabi M., 2015 and 2016. “Chemometric Analysis in Solid State Science and Crystallization Engineering”, Mettler Toledo Information Sharing Symposium, Iselin, NJ, and Cambridge, MA, USA.

  5. R. Alex Mayo, Kathryn E. Preuss, 2015. “Temperature Dependent Conformational Polymorphism of a 1,2,3-DTA Ligand”, North American Thermal Analysis Society (NATAS) Conference, Montreal, QC, Canada.

  6. Mirmehrabi M., 2014. “Particle Engineering for Improved and Consistent Drug Substance Quality”, Boston PBSS Workshop

  7. Batchu P., 2014. "Kinetic Distortion to Thermodynamic Predictions in Crystallizing Triglycerides", AOCS annual meeting and Expo, San Antonio, Texas, (Presented by Dr. Gianfranco Mazzanti).

  8. R. Alex Mayo, 2013. “Molecular Magnetism and Phase Change in Metal-Radical Complexes”, CNRS, CRPP, Université de Bordeaux, France.

  9. Batchu P., 2013. "Kinetic Phase Diagrams of Crystallizing Trilaurin-trimyristin Mixtures Using Small Angle X-ray Diffraction", IRM annual general meeting and research day, Halifax, Nova Scotia.

  10. Mirmehrabi M., 2012. “Controlling Oiling Out During Crystallization Process Development”, Mettler Toledo Information Sharing Symposium, Cambridge, MA, USA.

  11. Mirmehrabi M., 2011. “Crystallization and Drying of Hydrates”, Mettler Toledo Information Sharing Symposium, New Brunswick, NJ, USA.

  12. Mirmehrabi M., 2008. “Oiling Out: A Crystallization-Purification Challenge”, 58th Canadian Chemical Engineering Conference, Ottawa, Canada.

  13. Tadayon S., S. Deshmukh, M. Mirmehrabi, J. Liang, Y. Wang, Q. Yu, 2006. “Drying of Pharmaceutical Hydrates”, 13th International Process Development Conference, Rhode Island.

  14. Deshmukh S. and M. Mirmehrabi, 2006. “PAT Tools for Evaluation of Drug Substance Crystallization”, FDA Science, A Century of FDA Science, Washington DC, USA.

  15. Mirmehrabi M. and S. Tadayon, 2006. “Agglomeration of Pharmaceutical Microparticles, the Origin and Implications”, American Institute of Chemical Engineers Conference, Orlando, Florida, USA.

  16. Mirmehrabi M. and S. Rohani, 2006. “Thermodynamic Modeling and Prediction of Solubility of Organic Molecules and Pharmaceuticals”, American Institute of Chemical Engineers Conference, Orlando, Florida, USA.

  17. Mirmehrabi M., S. Tadayon, Q. Yu and S. Deshmukh, 2006. “Thermodynamic Insights into Crystalline Hydrates: a Case Study”, 56th Canadian Chemical Engineering Conference, Sherbrook, Canada.

  18. Rohani S. and Mirmehrabi M., 2005. “Polymorphic Behavior and Crystal Habit of an Anti-Viral/HIV Drug: Stavudine”, American Institute of Chemical Engineers Conference, Cincinnati, OH, USA.

  19. Rohani S. and M. Mirmehrabi, 2004. "Batch Crystallization in Pharmaceutical and Fine Chemicals Industries in Canada", Proceeding of International Technical Forum Inspiring Powder Technology, Tokyo, Japan.

  20. Mirmehrabi M. and S. Rohani, 2004. "Molecular Interactions Between Solvent and Pharmaceutical Compounds in Crystallization of Polymorphic Systems", American Institute of Chemical Engineers Conference, Austin, Texas, USA.

  21. Mirmehrabi M., S. Rohani, K.S.K. Murthy and B. Radatus, 2003. "Tautomeric Polymorphism of Ranitidine Hydrochloride", 53rd Canadian Chemical Engineering Conference, Hamilton, Canada.

  22. Mirmehrabi M. and S. Rohani, 2002. "Control of Polymorphism in Pharmaceutical Products", 52nd Canadian Chemical Engineering Conference, Vancouver, Canada.

  23. Rohani S. and M. Mirmehrabi, 2002. "Solid-Liquid Equilibrium of Stearic Acid Polymorphs in Organic Solvents", 52nd Canadian Chemical Engineering Conference, Vancouver, Canada.

Ready to collaborate? Let’s work together